Latest Beta secretase Stories
Gothenburg researchers have discovered a previously unknown substance in spinal fluid that can be used to diagnose Alzheimer's disease.
The destructive cellular pathways activated in Alzheimer's disease are also triggered following traumatic brain injury, say researchers from Georgetown University Medical Center
SCOTTSDALE, Ariz., June 12 /PRNewswire/ -- MedPredict Market Research, a global provider of pharmaceutical competitive intelligence and market research, has published a new report entitled "Thought Leader Insight & Analysis: Alzheimer's Disease," designed to provide critical strategic insight for pharma and biotech companies with a stake in the market for diagnostics and treatments in this disease area (http://www.medpredict.com/website/home.aspx).
Taking a new approach to the treatment and prevention of Alzheimer's disease, a research team led by investigators at the Mayo Clinic campus in Florida has shown that druglike compounds can speed up destruction of the amyloid beta (A-beta) proteins that form plaque in the brains of patients with the disorder.
New research at the Salk Institute for Biological Studies casts the role of a neuronal growth factor receptor â€” long suspected to facilitate the toxic effects of beta amyloid in Alzheimer's disease â€” in a new light, suggesting the molecule actually protects the neuron in the periphery from beta amyloid-induced damage.
A class of Alzheimer's disease drugs currently studied in clinical trials appears to reduce damage caused by traumatic brain injury in animals, researchers at Georgetown University Medical Center report in an upcoming advance online publication of Nature Medicine.
Scientists have identified an initiating molecular mechanism in sporadic Alzheimer's disease (AD). The study, published by Cell Press in the December 26th issue of the journal Neuron, provides new information about generation of damaging amyloid Ã² (AÃ²) plaques within the AD brain and underscores the importance of developing new preventative and disease-modifying therapies for AD, especially those aimed at interrupting pathological...
A slow, chronic starvation of the brain as we age appears to be one of the major triggers of a biochemical process that causes some forms of Alzheimer's disease.
SARASOTA, Fla., Oct. 21 /PRNewswire/ -- A team of world-renowned scientists today announced the launch of Archer Pharmaceuticals, Inc., a new company that will use modern technologies for the identification of novel treatments for Alzheimer's disease.
To: NATIONAL EDITORS Contact: Alzheimers Association media line: +1-312-335-4078, email@example.com; ICAD 2008 press room, July 27-31: +1-312-949-3253 CHICAGO, July 29/PRNewswire-USNewswire/ -- With the continued aging of the population and the growing epidemic of Alzheimers, early detection of the disease is crucial for risk assessment, testing new therapies, and eventual early intervention with better drugs, once they are developed.
- A serpent whose bite was fabled to produce intense thirst.